Stanley Black & Decker Inc (SWK) 120.92 $SWK Watch for

New Post Public Reply Private Reply Replies (0) Message Board

Sep 24, 2016 at 5:11 AM

Stanley Black & Decker Inc (SWK) 120.92 $SWK

Watch for The Stanley Works to Potentially Rebound After Falling 1.55% Yesterday
Comtex SmarTrend(R) - Fri Sep 23, 1:03PM CDT
The Stanley Works (NYSE:SWK) traded in a range yesterday that spanned from a low of $120.94 to a high of $122.64. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $121.13 on volume of 464,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SWK: 120.92 (-2.28)

Industrial Goods Stocks Technical Report -- Kennametal, Stanley Black & Decker, Timken, and Snap-on
PR Newswire - Thu Sep 22, 5:00AM CDT
Stock-Callers.com is currently looking at the Machine Tools and Accessories industry which produces and distributes tools used to manufacture other products in end-markets such as the housing and automotive segments. Equities in focus are: Kennametal Inc. (NYSE: KMT), Stanley Black & Decker Inc. (NYSE: SWK), The Timken Co. (NYSE: TKR), and Snap-on Inc. (NYSE: SNA). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
SWK: 120.92 (-2.28), KMT: 27.86 (-0.66), SNA: 151.79 (-1.01), TKR: 33.26 (-0.41)

26.5% Return Seen to Date on SmarTrend The Stanley Works Call (SWK)
Comtex SmarTrend(R) - Tue Sep 20, 12:48AM CDT
SmarTrend identified an Uptrend for The Stanley Works (NYSE:SWK) on March 1st, 2016 at $95.84. In approximately 7 months, The Stanley Works has returned 26.53% as of today's recent price of $121.26.
SWK: 120.92 (-2.28)

VizExplorer Announces Strategic Investment and Technology Development Agreement with Stanley Black & Decker
BusinessWire - Tue Sep 13, 5:00AM CDT
VizExplorer, a leading provider of operational intelligence solutions today announced that it has closed a strategic investment and technology development agreement with Stanley Black & Decker, a world-leading provider of tools and storage, commercial electronic security and engineered fastening systems.
SWK: 120.92 (-2.28)

The Stanley Works Has Returned 25.2% Since SmarTrend Recommendation (SWK)
Comtex SmarTrend(R) - Mon Sep 12, 1:35PM CDT
SmarTrend identified an Uptrend for The Stanley Works (NYSE:SWK) on March 1st, 2016 at $95.84. In approximately 7 months, The Stanley Works has returned 25.22% as of today's recent price of $120.00.
SWK: 120.92 (-2.28)

Stanley Black & Decker To Present At The 4th Annual Morgan Stanley Laguna Conference
PR Newswire - Thu Sep 08, 11:38AM CDT
Stanley Black & Decker (NYSE: SWK) invites investors and the general public to listen to a webcast of a presentation by Don Allan, Senior Vice President and CFO, at the 4th Annual Morgan Stanley Laguna Conference in Laguna Beach, CA on Thursday, September 15, 2016 at 1:25 pm PT. The live webcast will be available in the "Investors" section of the company's website at www.stanleyblackanddecker.com. A replay of the webcast will be provided on the website and will be available for 90 days.
SWK: 120.92 (-2.28), MS: 31.91 (-0.33)

Stanley Black & Decker's Prospects Solid, Risks Remain
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 8:55AM CDT
We have issued an updated research report on Stanley Black & Decker, Inc. (SWK) on Sep 6, 2016.
SWK: 120.92 (-2.28), TNC: 64.84 (-1.37), GRC: 26.03 (-0.02), DXPE: 25.23 (-0.55)

Uptrend Call Working As The Stanley Works Stock Rises 27.1% (SWK)
Comtex SmarTrend(R) - Fri Aug 26, 12:41AM CDT
SmarTrend identified an Uptrend for The Stanley Works (NYSE:SWK) on March 1st, 2016 at $95.84. In approximately 6 months, The Stanley Works has returned 27.08% as of today's recent price of $121.79.
SWK: 120.92 (-2.28)

Downgrade Alert for The Stanley Works (SWK)
Comtex SmarTrend(R) - Tue Aug 23, 3:01AM CDT
The Stanley Works (NYSE:SWK) was downgraded from Buy to Neutral at Longbow today. The stock closed yesterday at $121.68 on volume of 645,000 shares, below average daily volume of 1.1 million. In the past 52 weeks, shares of The Stanley Works have traded between a low of $88.72 and a high of $124.00 and closed yesterday at $121.68, which is 37% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 1.4% while the 200-day MA has remained constant.
SWK: 120.92 (-2.28)

The Stanley Works Up 27.4% Since SmarTrend Uptrend Call (SWK)
Comtex SmarTrend(R) - Thu Aug 18, 1:03PM CDT
SmarTrend identified an Uptrend for The Stanley Works (NYSE:SWK) on March 1st, 2016 at $95.84. In approximately 6 months, The Stanley Works has returned 27.35% as of today's recent price of $122.05.
SWK: 120.92 (-2.28)

Global Industrial Fasteners Market Report 2014-2020 - Analysis, Technologies & Forecasts - Key Vendors: Standard Fasteners, Stanley Black & Decker, Hilti - Research and Markets
BusinessWire - Wed Aug 17, 7:53AM CDT
Research and Markets has announced the addition of the "Industrial fasteners (Externally Threaded, Aerospace Grade, Standard and Others) Market 2014 - 2020" report to their offering.
SWK: 120.92 (-2.28)

The Stanley Works Shares Up 26.9% Since SmarTrend's Buy Recommendation (SWK)
Comtex SmarTrend(R) - Wed Aug 03, 12:59PM CDT
SmarTrend identified an Uptrend for The Stanley Works (NYSE:SWK) on March 1st, 2016 at $95.84. In approximately 5 months, The Stanley Works has returned 26.90% as of today's recent price of $121.61.
SWK: 120.92 (-2.28)

Rexnord (RXN) Beats Q1 Earnings & Revenues; Keeps View
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 6:46AM CDT
Rexnord Corporation's (RXN) adjusted earnings of 35 cents per share for first-quarter fiscal 2017 (ended Jun 30, 2016) surpassed the Zacks Consensus Estimate of 30 cents, while grew 9.4% year over year.
SWK: 120.92 (-2.28), FELE: 39.67 (-0.59), RXN: 20.65 (-0.14), AOS: 96.88 (-0.02)

Kennametal (KMT) Lags on Q4 Earnings but Beats Revenues
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 6:43AM CDT
Kennametal Inc. (KMT) reported adjusted earnings of 44 cents per share for fourth-quarter fiscal 2016 (ended Jun 30, 2016), lagging the Zacks Consensus Estimate of 45 cents; while revenues of $521 million beat the estimate of $516 million.
SWK: 120.92 (-2.28), KMT: 27.86 (-0.66), FELE: 39.67 (-0.59), AOS: 96.88 (-0.02)

Top 7 Research Reports for July 27, 2016
Sheraz Mian - Zacks Investment Research - Wed Jul 27, 1:01PM CDT
Top 7 Research Reports for July 27, 2016
RAI: 48.58 (-0.20), SWK: 120.92 (-2.28), ESRX: 71.34 (+0.31), HON: 115.98 (-0.85), CHK: 6.63 (-0.24), TXN: 68.98 (-0.78), VFC: 56.95 (+0.07)

Dow Takes a Break - How Will It End the Week?
Mark Vickery - ZACKS - Fri Jul 22, 4:01AM CDT
So the Dow finally closed lower at the bell on Thursday, and the Q2 earnings juggernaut finally brought some less-than-positive news.
SBUX: 54.43 (+0.04), SWK: 120.92 (-2.28), T: 41.28 (+0.17), V: 82.54 (-0.82), SKX: 22.09 (+0.16), CMG: 413.81 (+3.65), AAL: 35.55 (+0.30)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...